We have located links that may give you full text access.
Case Reports
Journal Article
Cerebrotendinous Xanthomatosis ataxia responsive to CDCA and Riluzole.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia 2018 July
Cerebrotendinous Xanthomatosis (CTX) is a rare genetic disorder due to mutations in the CYP27A1 gene resulting in both systemic and neurologic manifestations from accumulation and deposition of cholestanol in tissues. Chenodeoxycholic Acid (CDCA) is the standard medical therapy, resulting in decreased cholestanol synthesis, however, neurologic improvement is typically not seen. Riluzole may have a symptomatic benefit in ataxia from a presumed protective effect on Purkinje cells. To date, there are no reports of symptomatic improvement in CTX related ataxia following treatment with Riluzole. We report the case of a 45 year old woman diagnosed with CTX-related cerebellar ataxia. Therapy with CDCA and Riluzole resulted in quantifiable improvement on the Scale for the Assessment and Rating of Ataxia (SARA). Thus, in addition to the standard therapy with CDCA, the addition of Riluzole may have some therapeutic benefits for ataxia caused by CTX. Further controlled studies are needed.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app